Sher YP - Search Results

1

EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis.

Fan CC, Tsai ST, Lin CY, Chang LC, Yang JC, Chen GY, Sher YP, Wang SC, Hsiao M, Chang WC. Fan CC, et al. Among authors: sher yp. Redox Biol. 2020 Jul;34:101571. doi: 10.1016/j.redox.2020.101571. Epub 2020 May 16. Redox Biol. 2020. PMID: 32446175 Free PMC article.

2

Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes.

Sher YP, Shih JY, Yang PC, Roffler SR, Chu YW, Wu CW, Yu CL, Peck K. Sher YP, et al. Clin Cancer Res. 2005 Jan 1;11(1):173-9. Clin Cancer Res. 2005. PMID: 15671543

3

ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway.

Lin CY, Chen HJ, Huang CC, Lai LC, Lu TP, Tseng GC, Kuo TT, Kuok QY, Hsu JL, Sung SY, Hung MC, Sher YP. Lin CY, et al. Among authors: sher yp. Cancer Res. 2014 Sep 15;74(18):5229-43. doi: 10.1158/0008-5472.CAN-13-2995. Epub 2014 Jul 24. Cancer Res. 2014. PMID: 25060522

4

ADAM9 enhances CDCP1 protein expression by suppressing miR-218 for lung tumor metastasis.

Chiu KL, Kuo TT, Kuok QY, Lin YS, Hua CH, Lin CY, Su PY, Lai LC, Sher YP. Chiu KL, et al. Among authors: sher yp. Sci Rep. 2015 Nov 10;5:16426. doi: 10.1038/srep16426. Sci Rep. 2015. PMID: 26553452 Free PMC article.

5

A HLA-A2-restricted CTL epitope induces anti-tumor effects against human lung cancer in mouse xenograft model.

Sher YP, Lin SI, Chen IH, Liu HY, Lin CY, Chiang IP, Roffler S, Chen HW, Liu SJ. Sher YP, et al. Oncotarget. 2016 Jan 5;7(1):671-83. doi: 10.18632/oncotarget.6400. Oncotarget. 2016. PMID: 26621839 Free PMC article.

6

Elevation of β-galactoside α2,6-sialyltransferase 1 in a fructoseresponsive manner promotes pancreatic cancer metastasis.

Hsieh CC, Shyr YM, Liao WY, Chen TH, Wang SE, Lu PC, Lin PY, Chen YB, Mao WY, Han HY, Hsiao M, Yang WB, Li WS, Sher YP, Shen CN. Hsieh CC, et al. Among authors: sher yp. Oncotarget. 2017 Jan 31;8(5):7691-7709. doi: 10.18632/oncotarget.13845. Oncotarget. 2017. PMID: 28032597 Free PMC article.

7

ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis.

Chiu KL, Lin YS, Kuo TT, Lo CC, Huang YK, Chang HF, Chuang EY, Lin CC, Cheng WC, Liu YN, Lai LC, Sher YP. Chiu KL, et al. Among authors: sher yp. Oncotarget. 2017 Jul 18;8(29):47365-47378. doi: 10.18632/oncotarget.17648. Oncotarget. 2017. PMID: 28537886 Free PMC article.

8

EFHD2 promotes epithelial-to-mesenchymal transition and correlates with postsurgical recurrence of stage I lung adenocarcinoma.

Fan CC, Cheng WC, Huang YC, Sher YP, Liou NJ, Chien YC, Lin PS, Lin PS, Chen CH, Chang WC. Fan CC, et al. Among authors: sher yp. Sci Rep. 2017 Nov 6;7(1):14617. doi: 10.1038/s41598-017-15186-y. Sci Rep. 2017. PMID: 29097801 Free PMC article.

9

ADAM9 promotes lung cancer progression through vascular remodeling by VEGFA, ANGPT2, and PLAT.

Lin CY, Cho CF, Bai ST, Liu JP, Kuo TT, Wang LJ, Lin YS, Lin CC, Lai LC, Lu TP, Hsieh CY, Chu CN, Cheng DC, Sher YP. Lin CY, et al. Among authors: sher yp. Sci Rep. 2017 Nov 8;7(1):15108. doi: 10.1038/s41598-017-15159-1. Sci Rep. 2017. PMID: 29118335 Free PMC article.

10

Publisher Correction: EFHD2 promotes epithelial-to-mesenchymal transition and correlates with postsurgical recurrence of stage I lung adenocarcinoma.

Fan CC, Cheng WC, Huang YC, Sher YP, Liou NJ, Chien YC, Lin PS, Lin PS, Chen CH, Chang WC. Fan CC, et al. Among authors: sher yp. Sci Rep. 2018 Jan 18;8(1):1456. doi: 10.1038/s41598-018-19645-y. Sci Rep. 2018. PMID: 29348465 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

59 results

Search Page

Filters